Rationally Designed TLR4 Ligands for Vaccine Adjuvant Discovery

Adjuvant properties of bacterial cell wall components like MPLA (monophosphoryl lipid A) are well described and have gained FDA approval for use in vaccines such as Cervarix. MPLA is the product of chemically modified lipooligosaccharide (LOS), altered to diminish toxic proinflammatory effects while...

Descripción completa

Detalles Bibliográficos
Autores principales: Gregg, Kelsey A., Harberts, Erin, Gardner, Francesca M., Pelletier, Mark R., Cayatte, Corinne, Yu, Li, McCarthy, Michael P., Marshall, Jason D., Ernst, Robert K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424205/
https://www.ncbi.nlm.nih.gov/pubmed/28487429
http://dx.doi.org/10.1128/mBio.00492-17

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424205/
https://www.ncbi.nlm.nih.gov/pubmed/28487429
http://dx.doi.org/10.1128/mBio.00492-17

Ejemplares similares